Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. Co. has two drug candidates (gaboxadol and soticlestat) from pre-clinical proof of concept and either through trials or to the initiation of trials, whether by Co. or its collaborators. Co.'s drug candidates include: Soticlestat, which is an inhibitor of cholesterol 24 hydroxylase that modulates the excitatory signals involved in epilepsy, and thereby suppress seizures; and OV329, which is being developed for the treatment of seizures associated with Tuberous Sclerosis Complex and Infantile Spasms. The OVID stock yearly return is shown above.
The yearly return on the OVID stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OVID annual return calculation with any dividends reinvested as applicable (on ex-dates).
|